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History of Renal Transplantation 
Thomas E. Starzl / Anthony}. Demetris 
Renal transplantation carne from a series of steps that began to appear in the lit-
erature at the beginning of the 20th century. The steps were small, widely spread in 
time, and usually overlooked or condemned. As late as 1961, the Nobel Laureate, 
Macfarland Burnet, wrote in the New Eng/and Journal of Medicine that ". . . much 
thought has been given to ways by which tissues or organs not genetically and anti-
genetically identical with the patient might be made to survive and function in the 
alien environment. On the whole, the present outlook is highly unfavorable to suc-
cess .... ,,1 This opinion was published on the eve of the successful clinical renal 
trans plantations in 1962 and 1963 that extended this procedure beyond the occa-
sional identical and fraternal twin cases of the mid and late 1950s. Even then, these 
efforts provoked editorials questioning their inherent feasibility as well as their eth-
ical basis.:! 
• TWENTIETH CENTURY BEGINNINGS 
Heterotransplantation (Xenotransplantation) 
In fact. the trials of the early 1960s were already late in a long, but at first slowly un-
folding, story of whole-organ transplantation. The first known attempts at clinical re-
nal transplantation by vascular anastomoses were made between 1906 and 1923 with 
pig, sheep, goat. and subhuman primate donors. The first of these efforts were in 
France.! and Germany, I but others followed as summarized elsewhereK~-i None of the 
kidneys functioned for long, if at aiL and the human recipients died a few hours to 9 
days later. Although the biologic barrier to success was not understood. the applic-
ability of vascular suture techniques (from Alexis Carrel) and even the possibility of 
using pelvic implantation sites were either envisioned or actually practiced. No fur-
ther animal to human transplantations were tried again until 1963, when systematiC 
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and surprisingly successful clinical trials were made with chimpanzee6 and baboon 7.8 
kidneys. The eventual death of all of the recipients of animal organs ended renal 
xenotransplantation trials until the Baby Fae baboon heart xenotransplantation in 
the mid 1980s.9 
Homotransplantation (Allotransplantation) 
In 1936 Voronoy of Kiev, Russia,10 reported the transplantation of a kidney from a ca-
daver donor of B+ blood type to a recipient of 0+ blood type in violation of what have 
become accepted rules of tissue transfer. I I In addition, the donor had been dead for 
6 hours. The recipient died 48 hours later without making urine. Sporadic further ef-
forts at renal allotransplantation were made in the ensuing 15 years without effective 
immunosuppression, as documented by Groth5 and Hume et ai. 12 
This was the dawn of renal transplantation. However, the stage was being set for 
the sunrise. Although renal transplantation lay largely dormant until 1951, Rene Kuss 
et al 13 and Charles Dubost et al 14 of Paris and Marceau Servelle et al of Strasbourgl5 
carried out a series of cadaveric renal transplantations from convict donors after ex-
ecution by guillotine. The next year, the French physician, Jean Hamburger, working 
with the urologist Louis Michon at the Hospital Necker, Paris, reported transplanting 
a kidney from a live volunteer donor.16 The kidney, which was donated to a young 
man (named Marius) from his mother, functioned well and for 3 weeks before being 
rejected by the nonimmunosuppressed recipient. The kidney transplant procedure 
originally developed by Kuss and the other French surgeons was used for this pa-
tient. It has been performed hundreds of thousands of times since then, including for 
the celebrated identical (monozygotic) twin transplantations performed by Murray 
(Nobel Laureate, 1990) et al 17 in Boston. 
Visitors flocked to France in the early 1950s to learn first hand from this experi-
ence, including John Merrill. who observed the extraperitoneal pelvic operation (of-
ten called the Kuss procedure in Europe). This was described in the classic account 
by Hume and Merrill et all:.! of their first clinical trials at the Peter Bent Brigham 
Hospital. In the Boston operations, all but one of the transplants were placed in the 
thigh and revascularized from the femoral vessels. with urine drainage by skin 
ureterostomies. 12 The extensive discussion of the French experience by Hume et all:.! 
included acknowledgment of the French source of the vascular surgical technology 
in the person of Alexis Carrel (Nobel Laureate, 1912), III who had spent much of his 
professional life in the United States in transplantation research. Carrel understood 
that transplanted organ allografts were not permanently accepted. but he did not 
know why. 
Although the Peter Bent Brigham program postdated the early French efforts. 
the depth and serious intentions of the Harvard group were obvious in the report by 
Hume et al. 12 It contained observations on nine kidney allografts in nonimmu-
nosuppressed recipients. The first of these kidneys was transplanted into the nor-
mal location in the recipient after its removal for a lower ureteral carcinoma on 
March 30. 1951. by Dr. L. H. Doolittle. of Springfield. Massachusetts. The patient had 
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been undergoing short-term dialysis care at the Brigham, where the first artificial kid-
ney in the United States had been brought from Holland by Wilhelm KoHf and modi-
fied by Harvard engineers, as described in detail by Moore. 19 
The next eight renal allografts, all placed in the thigh location, were transplanted 
between April 23, 1951, and December 3, 1952. Hume's description of this experience 
stands as one of the great medical classics of the 20th century. It provides a nearly 
complete clinical and pathologic profile of renal allograft rejection in an untreated 
human recipient. None of the European and American efforts to this time, however, 
or all together, would have had any lasting impact on medical practice were it not for 
what lay ahead. The principal ingredients of organ transplantation-immunosup-
pression, tissue matching, and organ procurement (and preservation)-were still un-
known or undeveloped. The only examples of probable allograft function through 
1954 were provided first by one of the nonimmunosuppressed patients of Hume 
et al 12 whose graft in the thigh location functioned for 5 months and an even earlier 
patient treated in Chicago by Lawler et al20 about whom similar claims were consid-
ered implausible by later critics. Hume's career lasted well into the next era of trans-
plantation, until his death in May, 1973, near Los Angeles in the crash of a private 
plane. John Merrill drowned off the beach of a Caribbean island in 1984. 
The perception, if not the reality, of hopelessness was changed at the Peter Bent 
Brigham Hospital 2 days before Christmas 1954, when a kidney was removed from a 
healthy man by the urologist J. Hartwell Harrison and transplanted by Joseph E. 
Murray to the pelvic location of the donor's uremic identical twin brother; the 
nephrologist was John P. Merrill. 17.21 As in the earlier mother-to-son transplant in 
France, 16 no effort was made to preserve the transplanted kidney, which functioned 
promptly even though it underwent 82 minutes of warm ischemia time. According to 
Merrill et al, 17 the bold step of exploiting the principle of genetic identity for whole-
organ transplantation had been suggested by the recipient's phYSician, David C. 
Miller, of the Public Health Service Hospital. Boston. It already was well known that 
identical twins did not reject each others' skin grafts.22 To ensure identity, reciprocal 
skin grafting was performed on the Boston twins. Although the identical twin cases 
attracted worldwide attention, organ transplantation had reached a dead end. 
Further progress in the presence of an immunologic barrier would require effective 
immunosuppression. 
THE CONCEPT OF IMMUNOSUPPRESSION 
With Recipient Irradiation 
For Bone Marrow Tfllnsplantation 
The transition of tissue and organ transplantation from an exercise in futility to ten-
uous practicality was a slow process that began more than to years before Murray's 
identical twin case. The fundamental problem of transplantation was defined by 
Medawar (Nobel Laureate with Burnet. 1960) when he provided evidence in 1944 that 
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rejection is an immunologic event.23.24 In retrospect, every further development was 
a logical and inevitable extension of this concept. If rejection was an immune reac-
tion. why not protect the organ transplant by weakening the immune system? This 
was done with adrenal corticosteroids25.26 and total body irradiation,27 both of which 
prolonged skin graft survival in animals. 
However, the delay of rejection of rodent skin grafts was modest at best. Hopes 
were fanned when Billingham, Brent, and Medawar28 accomplished permanent skin 
allograft acceptance in a special circumstance not involving any immunosuppres-
sion; namely, the inoculation of fetal or perinatal mice with immunocompetent 
spleen cells from adult donors. Instead of being rejected, these cells survived in the 
immunologically immature reCipients, who were endowed with the ability in later life 
to accept skin from the original donor strain.28.29 This was the first example of ac-
quired transplantation tolerance. 
The impetus and rationale for these experiments came originally from the ob-
servation by Owen30 that freemartin cattle (the calf equivalents of human fraternal 
twins) were permanent hematopoietic chimeras if placental fusion and fetal cross cir-
culation had existed in utero. Burnet and Fenner31 predicted that such chimerism 
and the ability to exchange other tissues could be induced by the kind of experiment 
eventually performed with Medawar by Billingham and Brent. However, the surgical 
interest generated by the mouse tolerance experiments was quickly dampened when 
Billingham and Brent32 learned that the penalty for the infusion of donor splenocytes 
was lethal graft versus host disease (GVHD) unless there was close histocompatibil-
ity between the donor and the immunologically defenseless recipients. 
Immunosuppression was first exploited to achieve tolerance when in 1955 Main 
and PrehnJ3 simulated in adult (as opposed to fetal) mice an environment they 
likened to that in the perinatal Billingham-Brent-Medawar animals. The three steps 
were: first, to cripple the immune system with supralethal total body irradiation. next 
to rescue it with allogeneic bone marrow (producing a hematolymphopoietic 
chimera), and finally to engraft skin from the bone marrow donor strain. Although 
these efforts were successfuI,J:l·:l4 lethal GVHD could be avoided. as in the perinatal 
mouse model only by using histocompatible donors. Mannick et al:J5 extended these 
observations by producing bone marrow chimerism in a single irradiated beagle dog, 
followed by kidney allotransplantation from the original marrow donor. The dog sur-
vived for 73 days.:\5 Rapaport et al:l6 later showed that. as in the rodent models, this 
strate!:,'Y could not work unless perfectly tissue-matched canine marrow donors were 
used. usually litter mates. Efforts by Hume et al.:17 Rapaport et al.: lt; and others to 
broaden the acceptable histocompatibility requirements were totally unsuccessful-
leading to lethal GVHD. rejection. or both. 
Appreciation of the dilemma posed by the administration of bone marrow to cy-
toablated recipients caused a break in ranks in 1959-1962 between those interested 
in the treatment of hematologic disorders and those for whom bone marrow was 
only the means to the end of transplantation of a needed whole organ. From this 
point onward. the therapeutic philosophies of bone marrow and solid organ trans-
plantation took separate pathways-one dependent and the other seemingly inde-
pendent of classic chimerism-associated tolerance induction as defined by the 
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Billingham, Brent, and Medawar model. 29 In spite of the fact that only perfectly 
matched siblings could be used, clinical bone marrow transplantation was accom-
plished in 1963 by Mathe et al in Paris38 and in 1968 by Gatti et al in Minneapolis39 
and Bach at the University of Wisconsin.4o Successes by Thomas (Nobel Laureate, 
1990),41 van Bekkum,42 and others fueled the maturation of bone marrow transplan-
tation into accepted clinical therapy for hematologic diseases and an assortment of 
other indications. 
For Whole Organs 
In contrast to the hematologists, Murray et al43 attempted to use the Main-Prehn 
principle of recipient cytoablation with total body irradiation (fBI) plus bone mar-
row and kidney transplantation in two patients only, both in 1958. Sublethal TBI43,44 
without bone marrow was used for the next 10 kidney recipients. Although 11 of 12 
irradiated recipients died after 0-28 days, the survivor (who was not given bone mar-
row) had adequate renal function from the time his fraternal twin brother's kidney 
was transplanted in January 1959 until he died of arteriosclerotic heart disease in 
1979. The detailed description of this patient by Merrill et al in the New England 
Journal of Medicine45 was arguably the single most influential clinical case report in 
the transplantation literature, because this was the first time that the genetic barrier 
to transplantation had been breeched.43.44.46 Five months later, Hamburger et a1 47-49 
added a similar fraternal twin case. The second recipient had good renal function un-
til his death 26 years later from carcinoma of the urinary bladder. 
However, it was conceivable with these fraternal (dizygotic) twin recipients that 
their individual placentas had cross-circulated with those of their kidney donors dur-
ing gestation, like the circumstances in Owen's freemartin cattle. This suspicion was 
put to rest with the further extraordinary kidney transplant experience in France 
during 1960-1962 in which TBl was used without bone marrow reconstitution. 
Hamburger et al4H,49 succeeded with kidney transplantation from a sibling and a first-
cousin donor. The latter kidney (transplanted in February 1962) functioned for 18 
years before retransplantation was performed (without interim dialysis) on a patient 
who now is a member of the French parliament. He is the longest surviving kidney al-
lograft recipient (34 years) from that heroic era.;() 
Also in Paris, Rene Kuss et al;;lK!i~ had long-term survival of three of six irradi-
ated patients treated with kidney transplantation from January 1960 through 1961. 
This was a monumental achievement. because two of Kuss's long-surviving patients 
were given kidneys from nonrelated donors (the first in June 1960) that functioned 
for 17 and 18 months. During the critical period from January 1959 through the 
spring of 1962. the cumulative French experience was the principal (and perhaps the 
only) justification to continue clinical kidney transplantation trials (Table :!-J), By 
showing that bone marrow infusion was not a necessary condition for substantial 
prolongation of kidney grafts. the stage was set for the transition to drug therapy. In 
fact. Kuss was using ti-mercaptopurine (6-MP) and steroids as adjuvant therapy as 
early as 1960.' 1 
Those examining this period historically have been inclined to consider 
I 
~ : 
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TABLE 2-1 ... LONG SURVIVING HUMAN KIDNEY ALLOGRAFTS (BEFORE MAY 1962) 
Kidney 
Primary Survival 
Reported by Reference Date Donor Immunosuppression (years) 
Murray 43.44.46 January 24. 1959 Fraternal twin X-ray 20S 
Hamburger 47 June 29. 1959 Fraternal twin X-ray 25' 
Kuss 51 June 22. 1960 Unrelated X-ray (also 1.5 
6-MP. steroids) 
Hamburger 48 December 19. 1960 Mother Irradiation (also >1 
steroids) 
Kuss 51 March 12.1961 Unrelated Irradiation (also 1.5 
6-M P. steroids) 
Hamburger 49 February 12. 1962 Cousin Irradiation (also 15b 
steroids) 
Murray S3 April 5. 1962 Unrelated Imuran 1.5 
(azathioprine) 
6-MP. 6-mercaptopurine. 
• Died of cancer. 
b Patient alive after retransplantation of sister kidney (without interim dialysis) on March 28. 1977. 
irradiation-induced and drug-induced graft acceptance as different phenomena.5.44.46 
However, it seems certain that the Boston and Paris fraternal twin kidney recipients, 
as well as the 5 long-surviving non-twin French recipients, had achieved to variable 
degrees the kind of graft acceptance that later was seen in tens of thousands of drug-
treated humans after all kinds of whole-organ transplantation. The fact that the 
mechanism was the same has been appreciated only since it was discovered that ex-
tensive migration and survival of sessile tissue leukocytes (most obViously of den-
dritic cells) from graft to host (microchimerism) is the explanation of "acceptance" 
of all whole organs with any immunosuppressive modality.54-5H 
Chemicollmmunosuppression 
Because of the success (albeit limited) with kidney transplantation after TBI. it was 
not surprising that the search for immunosuppressive drugs was focused at first on 
myelotoxic agents that mimicked irradiation. They were viewed as "space makers" 
for donor marrow or for recovering recipient bone marrow. [n September 1960. 
Goodwin et al produced profound bone marrow suppression with methotrexate and 
cyclophosphamide in a daughter recipient of a maternal kidney. The patient subse-
quently experienced several rejections that were temporarily reversed with pred-
nisone during the 143 days of survival. This was the first example of protracted hu-
~ .. - .. - ... ----------
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man kidney graft function with drug treatment alone. 59 However, the case was not re-
ported until 1963. 
Kidney transplant surgeons were quick to realize that myelotoxicity should be 
avoided, not deliberately imposed. The most important step in this appreciation 
followed the discovery by Schwartz and Dameschek60 that 6-MP in nontransplant 
models was immunosuppressive without bone marrow depression. Within a few 
months, Schwartz and Dameschek61 and Meeker et al62 showed that 6-MP allowed 
a dose-related mitigation of skin-graft rejection in rats. Close behind, Calne63 and 
Zukoski et al64 independently demonstrated the same thing in dogs following kid-
ney transplantation. 
In June, 1960, Caine moved from the Royal Free Hospital, London, to Boston to 
be the team leader in Murray's Brigham laboratory for further preclinical develop-
ment of 6-MP and its analogue, azathioprine.65,66 What was achieved at first in Boston 
and in laboratories elsewhere with the canine kidney transplant model was delay of 
rejection or death of the animal from overimmunosuppression. However, occasional 
examples of long-term or seemingly permanent allograft acceptance were observed 
throughout 1962 and 196367- 7°-defined as long survival of transplanted mongrel kid-
neys folloWing completion of a 4- to 12-month course of 6-MP or azathioprine. The 
same thing has been observed since with each new major immunosuppressive agent 
(or drug cocktail regimen), including cyclosporine and tacrolimus (FK 506). Until the 
advent of cyclosporine and tacrolimus, the most potent agents for induction of this 
state have been the antilymphocyte sera (ALS) and antilymphocyte globulins (ALG) 
that at the beginning were polyclonal agents 71.72 and later the highly specific mono-
clonal preparations first used clinically by Cosimi et aL 73 
This new kind of graft acceptance in outbred dogs was easier to produce with 
drugs than with TBI, but the number of absolute examples was (and is) extremely 
small in contrast to what can be achieved in small rodents. In Murray's summary 
of his research with Caine and subsequent collaborators. a handful of long-
surviving animals «5%) was the distillation from 1000 experiments with 6-MP or 
azathioprine performed in the Boston laboratories. hi The same was true every-
where. The animals proudly displayed as long-term survivors in laboratories in 
Boston, Denver, Richmond, and Minneapolis were limited to a few who had run the 
gauntlet of therapy to the point where treatment was stopped. However, a unique 
observation was made at the University of Colorado. Adrenocortical steroids were 
shown to reverse rejection in 88 'X) of dogs, sometimes in a spectacular way. before 
the steroids in this species almost always caused fatal peptic erosions of the gas-
t rointestinal tract. 7·1 
It was on this dismal record that the clinical kidney transplant trials of the early 
1960s were based. In a display of optimism that would not he tolerated in today's 
clinical research climate. the rare exceptional survival was given more weight than 
the customary failure. Thus the poor results came as no surprise when the drugs 
were !lrst used for patients in the same way as had been tried in dogs. fl~:f However. 
olle of the Boston patients whose transplantation under azathioprine had been 
performed in April. 19fi2. had functional graft survival for more than I S months after 
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receiving the kidney of a patient who could not be weaned from a heart-lung appa-
ratus after open heart surgery53,75 under conditions comparable to those of a "heart-
beating cadaver."76 Although the allograft failed after 18 months. this pioneer recipi-
ent was the first to achieve long survival with azathioprine. and this constituted the 
opening wedge into a new era . 
... THE YEAR OF THE STAMPEDE: 1963 
The Crucial Role of Steroids 
The Reversibility of Rejection 
At the University of Colorado, where the synergism of azathioprine and prednisone 
had been observed in dog experiments,74 the two drugs were routinely used to-
gether from the origin of this program in early 1962. The results exceeded every-
one's expectations 77,78 and precipitated a revolution in clinical transplantation. 
Acute rejection could readily be reversed with prednisone in almost all cases. The 
use of adrenocortical steroids in transplantation can be traced to the experimental 
work a decade earlier of Billingham et al25 and Morgan.26 Goodwin et al 59 had ob-
served reversal of rejection in a kidney recipient whose primary treatment had been 
with methotrexate and cyclophosphamide. Hamburger et al4il and Kuss et al51 also 
had administered steroids to their irradiated patients under unknown circum-
stances. However, there was no hint in any of these reports suggesting either 
the profound effectiveness of prednisone or the indispensability of this dose-
maneuverable drug, which remains an essential component of treatment regimens 
to the present day. 
Host-Groft Nonreactivity 
A second and equally fundamental observation in the Colorado kidney recipients 
was a subsequent diminution in the amount of drug treatment required to prevent re-
jection," often allowing the life-time rehabilitation of many patients in an unre-
stricted environment. Of the first 64 patients in the Colorado series compiled be-
tween 1962 and March 1964,'1{ 15 survived for the next 25 years, including the 
recipient with the longest surviving allograft in the world (now 33 years ).so Two of 
the 15 patients stopped all immunosuppression without rejection for 28 and 30 years, 
recapitulating the phenomenon occasionally seen in dogs and in the irradiated 
Boston and Paris fraternal twins. Nine other patients from the era preceding early 
1964. including three treated by Hume (who had moved to Richmond), were alive in 
six other centers in the summer of 1989. None of these quarter-century survivors had 
been given a kidney from a nonrelated donor. The first such example in the world 
passed the :ZS-year mark in October 1989.·")11 This was a recipient of a cadaveric kid-
ney treated in Paris by Hamburger et al in October 1964. 
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TABLE 2-2 J.. THE FOUNDATION OF CLINICAL TRANSPLANTATION 
Central Therapeutic Dogma 
Therapy with baseline drugs 
Secondary adjustments with steroids with or without anti lymphoid agents 
Case to case trial (and potential error) of weaning 
Evolution of a Treatment Dogma 
Principal Baseline Agents 
Azathioprine 
Cyclophosphamide 
Cyclosporine 
Tacrolimus (FK 506) 
The reversibility of rejection and change in the host-graft relationship eventually 
were verified with all other transplanted organs, beginning with the Iiver.79.80 
Although immunosuppression has improved, the central therapeutic dogma for 
solid-organ transplantation that had emerged by 196377.78 has changed very little in 
more than 30 years. The dogma calls for daily treatment with one or two baseline 
drugs with further immune modulation by the highly dose-maneuverable adrenocor-
tical steroids to whatever level is required to maintain stable graft function (fable 
2-2). This means that every recipient of a whole organ goes through a trial and po-
tential error experience as drugs are weaned to maintenance levels. 
When the news became known in 1963 of the successes with azathioprine and 
prednisone therapy, a proliferation of kidney transplant centers began on both sides 
of the Atlantic. In January 1963, there were only three active clinical kidney trans-
plant centers in the United States. These were at the Brigham. the Medical College of 
Virginia (where Dave Hume moved from Boston in 1956), and the University of 
Colorado, where the first renal transplantation was performed in March 1962. 
Centers were equally scarce in Europe, where the two in Paris had been in existence 
for more than a dozen years. By year's end. more than 50 American kidney centers 
were gearing up, and some had already started. The same thing occurred in Europe. 
Trials with the liver, the next vital organ beyond the kidney, had started,HI and clini-
cal xenotransplantation with chimpanzee() and baboonH donors had been systemati-
cally tried with encouraging. although ultimately unsatisfactory results. 
Failure to explain the reason for the empirically derived treatment regimen did 
!lot prevent its worldwide acceptance almost overnight and its refinement to an art 
form with each new agent beginning with the addition of ALG in 1966 as a third (ad-
juvant) agent~1 and continuing in 1989 with the addition of tacrolimus (FK 5(6).":.' The 
introduction of cyclosporine by Caine et al~d in 1978 eventually led to a dramatic 
change in the neld. However. the use of cyclosporine alone (or in combinatiol\ with 
mvelotoxic agents) was unacceptably toxic and suboptimallv therapeutic. When 
combined with prednisone (with or without other agents ),S.I the new drug narrowed 
the gap between the results of cadaveric versus liVing-related transplantatioll dlld 
()pened the doors to fllrther development of transplantation of the liver. heart. and 
other t:'xtrarenal organs. 
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.. KIDNEY PROCUREMENT AND PRESERVATION 
The sudden arrival of clinical kidney transplantation in 1963 was so unexpected that 
little collateral research or other formal preparation had been made to preserve the 
organs. The lack of insight 50 years ago about the requirements for successful kidney 
preservation was illustrated by the fact that Voronoy's first cadaveric kidney donor 
(in 1936) had been dead for 6 hours before procurement.10 Even in the highly suc-
cessful identical twin cases, kidneys were not protected from warm ischemia until 
1962. 
Yet the potential benefit of lowering the temperature of an excised organ was 
grasped instinctively by early workers, in part because cardiac surgeons were knowl-
edgeable about hypothermia for open heart operations and had demonstrated a re-
duction of ischemic damage below the level of aortic cross clamping when the sub-
diaphagmatic organs were cooled.8s Lillehei et al86 simply immersed intestine in iced 
saline solution before its autotransplantation. The value of hypothermia for liver al-
lografts was quantified chemically by Sicular and Moore,87 who reported a slowed 
rate of enzyme degradation in cold hepatic slices. Thus the principle of hypothermia 
was understood, although not efficiently applied. 
Hypothermia to protect human renal homografts was first systematically ac-
complished with the cumbersome and potentially dangerous method of ice-tub im-
mersion of living volunteer donors.88 Total body hypothermia was soon replaced by 
core (intravascular) cooling by means of infusion of chilled solutions into the renal 
artery after donor nephrectomy.89 This technique (using lactated Ringer's solution) 
had been used for the first time during the development of experimental liver trans-
plantation.9o Its modification for the renal operation by the same team was an early 
example of the cross fertilization of procedures that continues today, despite the 
balkanization of transplantation along organ-defined specialty lines. 
Core cooling remains the first step in the preservation of all whole-organ grafts. 
In cadaveric donors, this is most often done in situ by means of some variation of the 
technique described by Marchioro et a1.91 This method for the continuous hy-
pothermic perfusion of cadaveric livers and kidneys was used clinically long before 
the acceptance of brain-death conditions.92 Ackerman and Snelfl3 and Merkel et al94 
popularized in situ cooling of cadaveric kidneys with simple infusion of cold elec-
trolyte solutions into the distal aorta. 
Until 1981, transplantation of the extrarenal organs was an unusual event. By late 
1981, it had become clear that liver and thoracic-organ transplant procedures were 
going to be widespread. A method of multiple organ procurement was required by 
which the kidneys, liver. heart. and lungs or various combinations of these organs 
could be removed without jeopardizing any of the individual organs. Such a system. 
called the flexible technique.<J5 was developed at the University of Colorado and the 
University of Pittsburgh. Aided by the efforts of C. Everett Koop. the Surgeon General 
of the United States. the technique was adopted as a worldwide standard almost 
overnight. All organs to be used are cooled in situ. and after cooling they are rapidly 
removed by means of dissection in a bloodless field. The sharing of organs from a 
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common donor by recipient teams from widely separated centers became routine by 
the mid 1980s. 
Extension of the safe period after initial cooling has followed one of two proto-
type strategies, developed in research conducted mainly with kidneys and applied 
secondarily to livers and other organs. One approach was to provide a limited and 
continuous renal arterial circulation, as was done by Ackerman and Barnard96 with a 
perfusate primed with blood and oxygenated within a hyperbaric oxygen chamber. 
When Belzer et al97 were able to eliminate the hemoglobin and hyperbaric chamber 
components, their asanguineous perfusion technique was immediately accepted but 
then slowly abandoned in most centers when it was learned that the quality of two-
day preservation was not markedly better than with the simpler and less expensive 
infusion and slush methods. Nevertheless, it is expected that refinement of this ap-
proach will someday allow true organ banking. 
The alternative strategy for the preservation of kidneys and other organs has 
been the instillation of special solutions such as that described by Collins et al98 or 
plasma-like solutions.\!9 The original Collins solution, or modifications of it, was used 
for almost 20 years for the so-called slush techniques of kidney preservation. The in-
troduction of the University of Wisconsin (UW) solution was the first important de-
velopment in kidney preservation in almost two decades. 
The superiority of the UW solution to any of previous conventional solutions for 
preservation of kidney, liver, and other organs has been demonstrated in experi-
mental kidney transplant test models 100-102 and confirmed in clinical trials. 103 The 
UW preservation allowed longer safe preservation (2 days), a higher rate of graft sur-
vival, and a lower rate of primary nonfunction. The day of economical and practical 
national organ sharing had finally arrived after 30 years of evolution . 
... TISSUE TYPING 
Antigen Matching 
In the early 1960s, when the modern era of transplantation was in its infancy, it was 
predicted that tissue matching would have to be perfected if kidney grafting proce-
dures were to succeed with any degree of reliability and predictability. The first 
prospective matching trials were started in 1964 by Terasaki et ai, \04 of Los Angeles, 
in collaboration with the University of Colorado transplantation team. 
The results were disappointing. Since then, the genetics of the human major his-
tocompatibility complex (MHC), its overriding importance in human biology, and 
above all its complexity have been established. Although the value of tissue match-
ing for transplantation between highly compatible family or nonrelated donor mem-
bers (the perfect match) was established as early as 1970,ItlS the complexity of the 
human histocompatibility system has militated against perfect matching between 
nonrelated people for cadaveric kidney transplantation. Lesser degrees of matching 
have not correlated well with outcome. 11iti-ItI'1 
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Whether these expensive efforts at matching should continue has become a de-
bated public policy because of the increasing use by the United Network of Organ 
Sharing (UNOS) of tissue matching as the overriding determinant of national distri-
bution of cadaveric kidneys. Reports from two American and European multicenter 
case compilations with an overlapping database have consistently claimed a slight 
but statistically significant gain in survival of well-matched versus mismatched 
cadaveric kidneys, but most of the centers or consortia that contribute to these data 
pools are unable to see this trend in their own material. In the meanwhile, the results 
with modern-day immunosuppression have become almost as good with unmatched 
cadaveric kidneys as with kidneys from less than perfectly matched (double haplo-
type identical) blood relatives. 
The most nagging intellectual concern to kidney transplant surgeons and others 
who wanted to but could not see an influence of human leukocyte antigen (HLA) 
matching in their own practices was the knowledge that only a perfect or near per-
fect match had a significant effect on outcome, and even then a small one. It was dif-
ficult to see why HLA matching was so critical for success with bone marrow trans-
piantation41 ,110 but so inconsequential for whole organs. A plaUSible explanation for 
this dichotomy was provided with the discovery of systemic chimerism in organ re-
cipients many years after organ transplantation. 54-56 How this chimeric state, which 
is believed to be the basis of renal graft acceptance, explains the blindfolding of an 
HLA matching effect is discussed in Chapter 9. 
(ross Matching 
None of the immunosuppressive measures available today can prevent the immedi-
ate destruction of kidneys by preformed humoral antibodies in what has been called 
hyperacute rejection. This catastrophiC complication was first seen with transplanta-
tion from ABO incompatible donors and ascribed to antidonor isoagglutinins. 11 After 
the description by Terasaki et alii I of hyperacute kidney rejection by a reCipient with 
antidonor Iymphocytotoxic antibodies, Kissmeyer-Nielsen et alii:! and others l13-115 
confirmed the etiologic role of these antigraft antibodies. Although hyperacute re-
jection usually can be avoided with the "cross match" originally recommended by 
Terasaki et al. III its exact pathogenesis remains mysterious 3D years later. Under-
standing and prevention of the process is believed to be the key to successful xeno-
transplantation. 11(; 
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